Literature DB >> 19321659

Optimising treatment regimens for the management of advanced gastric cancer.

R Wong, D Cunningham.   

Abstract

Entities:  

Mesh:

Year:  2009        PMID: 19321659     DOI: 10.1093/annonc/mdp203

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  HNRNPC as a candidate biomarker for chemoresistance in gastric cancer.

Authors:  Hao Huang; Yong Han; Cheng Zhang; Jian Wu; Junnan Feng; Like Qu; Chengchao Shou
Journal:  Tumour Biol       Date:  2015-10-09

2.  High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.

Authors:  Hao Huang; Yong Han; Jing Gao; Junnan Feng; Lei Zhu; Like Qu; Lin Shen; Chengchao Shou
Journal:  Med Oncol       Date:  2013-10-18       Impact factor: 3.064

3.  HNRNPK inhibits gastric cancer cell proliferation through p53/p21/CCND1 pathway.

Authors:  Hao Huang; Yong Han; Xingjiu Yang; Mengyuan Li; Ruimin Zhu; Juanjuan Hu; Xiaowei Zhang; Rongfei Wei; Kejuan Li; Ran Gao
Journal:  Oncotarget       Date:  2017-10-17

4.  Profiling chemotherapy-associated myelotoxicity among Chinese gastric cancer population receiving cytotoxic conventional regimens: epidemiological features, timing, predictors and clinical impacts.

Authors:  Ci Zhu; Yan Wang; Xicheng Wang; Chunmei Bai; Dan Su; Bing Cao; Jianming Xu
Journal:  J Cancer       Date:  2017-08-18       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.